Search
Displaying 291–300 of 865 results
-
Investigators Report Partial Vision Restoration for One Patient in Optogenetic Therapy Trial
Eye On the Cure Research NewsThe gene-agnostic approach is designed to restore some vision to people with advanced vision loss
-
Girl Scouts are Changing the World One Crosswalk at a Time
Beacon StoriesInspired by their troop leader diagnosed with Usher syndrome, Girl Scout Troop 1673 is hoping to change the world, one crosswalk at a time, with their Paint It Yellow challenge.
-
New Bipartisan Legislation Introduced to Boost Clinical Research for Treatments and Cures
Industry NewsThe bill would provide loans to therapy developers ready to launch clinical trials for a broad range of conditions including eye diseases.
-
Foundation Fighting Blindness Applauds Introduction of LOANS for Biomedical Research Act
Press ReleasesLegislation provides innovative financing for clinical trials stalled by COVID-19 pandemic.
-
Landing Page
The bill would provide loans to therapy developers ready to launch clinical trials for a broad range of conditions including retinal and eye diseases.
-
Press Releases
The free webinar for eye care professionals, on June 21, will feature some of the intriguing and innovative research efforts underway for inherited retinal diseases and AMD.
An overview of the Foundation’s no-cost genetic testing program will also be presented.
-
The Foundation in the News
Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness. Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atlas Venture, Mission BioCapital and Foundation Fighting Blindness.
-
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
Eye On the Cure Research NewsMore details from the clinical trial will be reported at a later date
-
AGTC Continues to Report Encouraging Data from its Phase 1/2 XLRP Gene Therapy Clinical Trial
Eye On the Cure Research NewsThe company is planning the launch of a Phase 2/3 trial for its XLRP gene therapy
